Patient enrollment for global clinical trials is up 85 percent from the trough in April, the lowest point for clinical trial enrollment during the COVID-19 pandemic, according to a new survey.

The rebound to pre-COVID levels has largely been driven by increased implementation of decentralized trial protocols. A survey report from study management firm Greenphire shows that 84 percent of 158 sponsors and CROs across 25 countries are actively working on increasing their use of virtual tools to support decentralized trials.

The survey found that trends in new patient enrollment for global trials have surpassed enrollment trends reported in January by up to 3 percent. Europe is up 6 percent in new patient enrollment compared with January, while North America is up 5 percent.

The recovery is particularly striking considering that a previous Greenphire survey had shown that 71 percent of sponsors and CROs had paused existing study enrollments and 58 percent of respondents had delayed study starts.

For more information about the survey, click here: https://bit.ly/3oFmmr7.